Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors have been reported by Shanghai Jemincare Pharmaceuticals Co. Ltd. to be potentially useful for the treatment of cancer, fibrosis, inflammation, pain, neurodegeneration, autoimmune, metabolic and cardiovascular disorders, among others.